Your browser doesn't support javascript.
loading
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Semmrich, Monika; Marchand, Jean-Baptiste; Fend, Laetitia; Rehn, Matilda; Remy, Christelle; Holmkvist, Petra; Silvestre, Nathalie; Svensson, Carolin; Kleinpeter, Patricia; Deforges, Jules; Junghus, Fred; Cleary, Kirstie L; Bodén, Mimoza; Mårtensson, Linda; Foloppe, Johann; Teige, Ingrid; Quéméneur, Eric; Frendéus, Björn.
Afiliação
  • Semmrich M; Department of Research, BioInvent International AB, Lund, Sweden.
  • Marchand JB; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Fend L; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Rehn M; Department of Research, BioInvent International AB, Lund, Sweden.
  • Remy C; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Holmkvist P; Department of Research, BioInvent International AB, Lund, Sweden.
  • Silvestre N; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Svensson C; Department of Research, BioInvent International AB, Lund, Sweden.
  • Kleinpeter P; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Deforges J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Junghus F; Department of Research, BioInvent International AB, Lund, Sweden.
  • Cleary KL; Antibody and Vaccine Group, Centre for Cancer Immunology, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Bodén M; Department of Research, BioInvent International AB, Lund, Sweden.
  • Mårtensson L; Department of Research, BioInvent International AB, Lund, Sweden.
  • Foloppe J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Teige I; Department of Research, BioInvent International AB, Lund, Sweden.
  • Quéméneur E; Department of Research, Transgene SA, Illkirch-Graffenstaden, France.
  • Frendéus B; Department of Research, BioInvent International AB, Lund, Sweden bjorn.frendeus@bioinvent.com.
J Immunother Cancer ; 10(1)2022 01.
Article em En | MEDLINE | ID: mdl-35058324
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Apresentação de Antígeno / Antígeno CTLA-4 / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Apresentação de Antígeno / Antígeno CTLA-4 / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia